CFAR Overview ABSTRACT This competing renewal application for the Penn Center for AIDS Research (CFAR) builds on an outstanding record of dynamic scientific leadership, organizational structure, resources and infrastructure that advance HIV/AIDS research across the integrated campus of the University of Pennsylvania, Children's Hospital of Philadelphia & the Wistar Institute. The CFAR's mission is to catalyze cutting-edge science and add value to the AIDS research enterprise through activities that could not be achieved by individual investigators or research projects. The Center is comprised of 250 members from our 3 institutions, including 11 of the 12 Penn schools and 17 departments within the School of Medicine, and key partners. The success of the CFAR in the last 5 years is reflected in >$200M in AIDS-related NIH funding over that time, key discoveries in AIDS research priority areas including HIV cure, vaccine development, immune reservoirs, bio-behavioral prevention & engagement in care, HIV coinfections/comorbidities & other areas, and 3 interdisciplinary Scientific Working Groups with high impact outcomes including funding of a Martin Delaney Collaboratory. Looking ahead, a comprehensive strategic planning process has led us to refine CFAR priorities, Core activities, and Core leadership to leverage new expertise and cultivate new research leaders, and maintain a cutting-edge focus for our SWGs. The Penn CFAR is now well-positioned to address critical challenges during the next 5 years. Our CFAR recently established two new SWGs (?Technology to Reduce HIV Disparities? & ?HIV Reservoirs & Tissue Immunology?) that have already achieved high impact discoveries and will be carried forward to the next cycle. The CFAR supports a Developmental Core and 7 Shared Resource Cores (Clinical, Virus & Reservoirs, Immunology, Prevention Science & Community Outreach, Biostatistics & Data Science, Nonhuman Primate, and International) that provide essential support for the research mission. The CFAR is led by Drs. Ronald Collman (Director) and Robert Gross (Co-Director) and governed by an Executive Committee with input from an Internal Advisory Board, External Advisory Committee and Community Advisory Board. The Penn CFAR has 4 highly inter-linked Specific Aims that enable it to achieve its mission: (1) Provide scientific and administrative leadership and pilot funding to catalyze innovative, interdisciplinary research that will lead to new knowledge and solutions for the AIDS crisis; (2) Attract, train, mentor and support the next generation of HIV/AIDS researchers to ensure forward-looking scientific progress, draw non-AIDS investigators into the field with cross-cutting interdisciplinary expertise, and launch the next generation of research leaders; (3) Support, monitor and continually evolve a set of efficient, dynamic & innovative Shared Resource Cores that both support HIV/AIDS investigators and lead the research agenda through development & dissemination of innovative technology that transforms scientific capacity, and; (4) Advance science and synergy through intra- campus, local, national & international partnerships, community engagement and capacity building.

Public Health Relevance

The CFAR's mission is to advance cutting-edge HIV/AIDS research on the Penn/CHOP/Wistar campus that will contribute innovative solutions to the AIDS crisis. The CFAR achieves this mission by providing scientific and administrative leadership to generate new research directions and collaborations; providing shared resource cores that support research through critical enabling technologies; leveraging institutional resources; training and mentoring the next generation of researchers and leaders and attracting scientists from other fields; and establishing partnerships and generating synergy with other groups on campus, in Philadelphia, nationally and internationally.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI045008-22
Application #
9925274
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Wong, Elaine Wai-Ken
Project Start
1999-07-01
Project End
2024-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
22
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Fraietta, Joseph A; Nobles, Christopher L; Sammons, Morgan A et al. (2018) Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558:307-312
Kelly, Matthew S; Surette, Michael G; Smieja, Marek et al. (2018) Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana. Pediatr Infect Dis J 37:1176-1183
Chitre, Avantika S; Kattah, Michael G; Rosli, Yenny Y et al. (2018) A20 upregulation during treated HIV disease is associated with intestinal epithelial cell recovery and function. PLoS Pathog 14:e1006806
Milligan, Michael G; Bigger, Elizabeth; Abramson, Jeremy S et al. (2018) Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana. J Glob Oncol :1-11
Medvec, Andrew R; Ecker, Christopher; Kong, Hong et al. (2018) Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium. Mol Ther Methods Clin Dev 8:65-74
Washio, Yukiko; Novack Wright, Elizabeth; Davis-Vogel, Annet et al. (2018) Prior Exposure to Intimate Partner Violence Associated With Less HIV Testing Among Young Women. J Interpers Violence :886260518768564
Wendel, Ben S; Del Alcazar, Daniel; He, Chenfeng et al. (2018) The receptor repertoire and functional profile of follicular T cells in HIV-infected lymph nodes. Sci Immunol 3:
Uzzan, Mathieu; Tokuyama, Minami; Rosenstein, Adam K et al. (2018) Anti-?4?7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals. Sci Transl Med 10:
Vadrevu, Surya Kumari; Trbojevic-Akmacic, Irena; Kossenkov, Andrew V et al. (2018) Frontline Science: Plasma and immunoglobulin G galactosylation associate with HIV persistence during antiretroviral therapy. J Leukoc Biol 104:461-471
Loy, Dorothy E; Plenderleith, Lindsey J; Sundararaman, Sesh A et al. (2018) Evolutionary history of human Plasmodium vivax revealed by genome-wide analyses of related ape parasites. Proc Natl Acad Sci U S A 115:E8450-E8459

Showing the most recent 10 out of 775 publications